| Product Code: ETC9936654 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 United Arab Emirates (UAE) Country Macro Economic Indicators |
3.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.7 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Favorable government regulations and initiatives supporting the adoption of mRNA vaccines and RNAi therapeutics in the UAE |
4.2.2 Increasing investments in research and development for advanced healthcare solutions |
4.2.3 Growing awareness and acceptance of personalized medicine and precision healthcare approaches in the UAE |
4.3 Market Restraints |
4.3.1 High costs associated with the development and production of mRNA vaccines and RNAi therapeutics |
4.3.2 Limited availability of skilled professionals and infrastructure for advanced biotechnology research and production in the UAE |
5 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Trends |
6 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market, By Types |
6.1 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F |
6.1.4 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F |
6.1.5 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F |
6.1.6 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F |
6.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market, By Administration |
6.2.1 Overview and Analysis |
6.2.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F |
6.2.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market, By End user |
6.3.1 Overview and Analysis |
6.3.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.3.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
7 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries |
7.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries |
8 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
8.1 Number of research partnerships and collaborations between local institutions and global biotech companies in the field of mRNA vaccines and RNAi therapeutics |
8.2 Rate of adoption of personalized medicine practices in healthcare facilities across the UAE |
8.3 Percentage of healthcare budget allocated towards advanced biotechnology solutions in the UAE |
9 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
9.1 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.3 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
10.1 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 United Arab Emirates (UAE) mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here